

Top 25 Drugs by 2021 Medicare Spend & Status Under IRA (\$M)

Drug	Company	TA	Primary Pathway	Modality Under IRA	'21 Gross Spend	% YoY Growth	'27 IRA Status	FDA Approval Year	Est. Discount Floor	Est. LOE	Est. Patent Impact (Years)	Generic Available Today?	Comments
Eliquis		Cardiovascular	Part D	Small Molecule	\$12,575	26.6%	Selected	2012	35.0%	2028	2	No	
Revlimid		Oncology	Part D	Small Molecule	\$5,894	10.0%	Not Eligible	2005	Not Eligible	2022	N/A	Yes	
Xarelto		Cardiovascular	Part D	Small Molecule	\$5,226	11.2%	Selected	2011	35.0%	2024	N/A	No	
Humira		Autoimmune	Part D	Biologic	\$4,732	13.6%	Not Eligible	2002	Not Eligible	2023	N/A	Yes	Incl. multiple formulations
Trulicity		CVMB	Part D	Biologic	\$4,702	43.1%	Eligible	2014	35.0%	2027	0	No	
Januvia		Metabolic	Part D	Small Molecule	\$4,060	5.0%	Selected	2006	60.0%	2026	0	No	
Keytruda		Oncology	Part B	Biologic	\$4,035	13.4%	Not Eligible	2014	Not Eligible	2028	N/A	No	Ineligible b/c Part B starts '28
Lantus		Metabolic	Part D	Biologic	\$3,790	1.9%	Not Eligible	2000	Not Eligible	2015	N/A	Yes	Incl. multiple formulations
Jardiance		CVMB	Part D	Small Molecule	\$3,736	57.2%	Selected	2014	25.0%	2028	2	No	
Eylea		Ophthalmology	Part B	Biologic	\$3,447	13.4%	Not Eligible	2011	Not Eligible	2025	N/A	No	Ineligible b/c Part B starts '28
Imbruvica		Oncology	Part D	Small Molecule	\$3,150	6.3%	Selected	2013	35.0%	2032	6	No	
Novolog		Metabolic	Part D	Biologic	\$2,853	(4.0%)	Selected	2000	60.0%	2014	N/A	No	Incl. multiple formulations
Ozempic		Metabolic	Part D	Small Molecule	\$2,622	80.1%	Eligible	2017	25.0%	2032	5	No	
Xtandi		Oncology	Part D	Small Molecule	\$2,411	22.5%	Eligible	2012	35.0%	2027	0	No	
Trelegy Ellipta		Respiratory	Part D	Small Molecule	\$2,393	60.9%	Eligible	2017	25.0%	2027	0	No	
Prolia		Musculoskeletal	Part B	Biologic	\$2,220	11.2%	Eligible	2010	60.0%	2025	N/A	No	Eligible via Part D (>\$250M)
Biktarvy		HIV	Part D	Small Molecule	\$2,198	23.8%	Eligible	2018	25.0%	2033	6	No	9Y post-launch in 2027
Myrbetriq		Urinary	Part D	Small Molecule	\$1,989	13.7%	Not Eligible	2012	Not Eligible	2022	N/A	Yes	
Symbicort		Respiratory	Part D	Small Molecule	\$1,952	(1.4%)	Not Eligible	2006	Not Eligible	2014	N/A	Yes	
Ibrance		Oncology	Part D	Small Molecule	\$1,891	(10.3%)	Eligible	2015	25.0%	2027	0	No	
Stelara		Autoimmune	Part D	Biologic	\$1,834	29.1%	Selected	2009	60.0%	2023	N/A	Upcoming	Biosimilars in 2025
Entresto		Cardiovascular	Part D	Small Molecule	\$1,723	43.2%	Selected	2015	25.0%	2025	N/A	No	
Restasis		Ophthalmology	Part D	Small Molecule	\$1,696	12.5%	Not Eligible	2002	Not Eligible	2014	N/A	Yes	Incl. multiple formulations
Opdivo		Oncology	Part B	Biologic	\$1,607	(1.0%)	Not Eligible	2014	Not Eligible	2028	N/A	No	Ineligible b/c Part B starts '28
Pomalyst		Oncology	Part D	Small Molecule	\$1,595	9.7%	Eligible	2013	35.0%	2026	N/A	No	

Note: Enbrel (Amgen) and Farxiga (AstraZeneca) also selected for negotiation, but not in the top 25 based on 2021 Medicare spend; gross spend does not reflect rebates / discounts and is not reflective of revenue to manufacturers

 Already selected